Cargando…
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
LTX-315 has been developed as an amphipathic cationic peptide that kills cancer cells. Here, we investigated the putative involvement of mitochondria in the cytotoxic action of LTX-315. Subcellular fractionation of LTX-315-treated cells, followed by mass spectrometric quantification, revealed that t...
Autores principales: | Zhou, Heng, Forveille, Sabrina, Sauvat, Allan, Sica, Valentina, Izzo, Valentina, Durand, Sylvère, Müller, Kevin, Liu, Peng, Zitvogel, Laurence, Rekdal, Øystein, Kepp, Oliver, Kroemer, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694939/ https://www.ncbi.nlm.nih.gov/pubmed/26378049 |
Ejemplares similares
-
The oncolytic peptide LTX-315 triggers immunogenic cell death
por: Zhou, H, et al.
Publicado: (2016) -
Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015) -
The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells
por: Eike, Liv-Marie, et al.
Publicado: (2015) -
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017) -
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014)